Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs

Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates and Du...Подробнее

Molecular Classification of Endometrial Cancer and Targeted Therapy ConsiderationsПодробнее

Antibody-drug conjugates in gynecological cancersПодробнее

The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLCПодробнее

Importance of understanding molecular subtypes in endometrial cancerПодробнее

New research could change how endometrial cancer is treatedПодробнее

FRa expression and sequencing ADCs in endometrial cancerПодробнее

Adrenal Metastasis from Uterine CancerПодробнее

Antibody-Drug Conjugates and Endometrial Cancer: Combinations, Response Rates, and Clinical TrialsПодробнее

6 Signs of EndometriosisПодробнее

Uterine cancer treatment showing great promiseПодробнее

Clinical Investigators Provide Perspectives on Management of Endometrial CancerПодробнее

ESGO 2011: Targeted treatments in endometrial cancerПодробнее

Molecular classification and adjuvant treatment in endometrial cancerПодробнее

HER2-targeting ADCs for urothelial carcinomaПодробнее

SGO 2013 - Endometrial CancerПодробнее

How Different Factors Affect Treatment of Endometrial CancerПодробнее

What Do We Need to Know About New Therapeutics for Patients With Endometrial Cancer?Подробнее

Precision oncology in endometrial cancerПодробнее